# MEDANTA (MEDANTA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/medanta

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,501
- Change: +5.41%
- As of: 2026-09-18
- 1D return: +5.29%
- 5D return: +2.73%
- 1M return: +6.48%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Medanta's stock is trading above key moving averages across daily, weekly, and monthly timeframes, indicating a generally positive technical stance. The daily and weekly charts show prices above their respective Supertrend indicators, supporting a bullish trend on these shorter-term periods. However, the monthly timeframe shows the price below its Supertrend, suggesting a potential conflict or a longer-term consolidation phase.

On the daily chart, the price is above the 20-day Exponential Moving Average (EMA) (1441.47) and the 50-day EMA (1406.22), with positive slopes on the SMAs. The weekly chart also shows prices above the 20-day EMA (1356.44) and 50-day EMA (1272.9), with strong upward slopes on the SMAs, reinforcing bullish momentum in the medium term. The monthly chart shows the price above the 20-day EMA (1240.54), but the overall trend direction is indicated as bearish by the monthly Supertrend.

Nearest support is observed around ₹1474.23 (1.68% below the current price), followed by ₹1456.27 (2.88% below). Resistance is noted at ₹1544.0, approximately 2.97% above the current price. The stock has experienced an extreme upward gap of 5% on September 18, 2026, with a Z-score of 4.01. Recent market activity shows 3 positive attention events in the last 30 days, with no downside or neutral events.

The stock's risk profile includes an annualized volatility of 32% and an Average True Range (ATR) of 3.28%. The current drawdown is minimal at -1%, while the maximum drawdown observed was -33%. The stock is positioned at the higher end of its recent trading ranges, with its position in the 20-day range at 73% and in the 252-day range at 92%.

- Current price on September 18, 2026: ₹1499.4
- Nearest support level: ₹1474.23 (1.68% below current price)
- Nearest resistance level: ₹1544.0 (2.97% above current price)
- Daily and weekly timeframes show bullish trends with prices above key moving averages and Supertrend.
- Monthly timeframe shows price above short-term EMAs but below the monthly Supertrend, indicating a mixed longer-term trend.
- An extreme upward gap of 5% occurred on September 18, 2026.

- Inside Bar
- Outside Bar
- Harami
- Bearish Engulfing Reversal
- Morning Star
- Doji

### News Context

Global Health Limited (Medanta) held its 22nd Annual General Meeting on September 16, 2026. During the meeting, shareholders approved the audited financial statements for the fiscal year ending March 31, 2026, and declared a final dividend of ₹0.50 per equity share. The re-election of Mr. Pankaj Sahni as a director and the remuneration for cost auditors for the 2026-27 financial year were also approved. Voting results, confirmed by a scrutinizer's report dated September 16, 2026, showed overwhelming support for these resolutions, with the dividend resolution passing with 99.9997% of valid votes in favour. Separately, the company's management is scheduled to engage with institutional investors. On September 17, 2026, management attended the Jefferies India Forum 2026, and on September 18, 2026, they participated in the Kotak Healthcare Forum 2026. Additionally, a one-on-one meeting with USS Investment Management Ltd is planned for September 23, 2026. No unpublished price-sensitive information is expected to be shared in these investor interactions.

- Global Health Limited's 22nd Annual General Meeting on September 16, 2026, saw shareholder approval for the FY26 audited financials and a final dividend of ₹0.50 per equity share.
- Mr. Pankaj Sahni was re-elected as a director, and cost auditor remuneration for FY27 was approved at the AGM.
- The dividend resolution at the AGM received 99.9997% approval, with 23,99,63,576 votes in favour.
- Management participated in the Jefferies India Forum 2026 on September 17, 2026, and the Kotak Healthcare Forum 2026 on September 18, 2026.
- A meeting with USS Investment Management Ltd is scheduled for September 23, 2026, with no price-sensitive information to be disclosed.

- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Global Health Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 16, 2026 |SUBJECT: Shareholders meeting
- Global Health Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 16, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### What Changed

As of September 18, 2026, Global Health, trading under the symbol MEDANTA on the NSE, has seen its stock price increase to ₹1499.4 from a previous price of ₹1424.0. This represents a recent upward movement in the stock's valuation. The company's profile and exchange listing remain consistent with prior context.

- On 2026-09-18, the stock price for MEDANTA was ₹1499.4.
- The stock price on the preceding observation date was ₹1424.0.
- Global Health is listed on the NSE under the symbol MEDANTA.

### Official Filings

Global Health Limited (Medanta) has recently disclosed its participation in several investor and analyst meetings. These engagements, scheduled between September 14 and September 23, 2026, involve meetings with entities such as USS Investment Management Ltd, Polar Capital, and Chikara Investments, as well as participation in the Jefferies India Forum 2026 and Kotak Healthcare Forum 2026. The company has explicitly stated that no unpublished price-sensitive information will be shared during these interactions. Additionally, the company held its 22nd Annual General Meeting on September 16, 2026. During this meeting, shareholders approved the audited financial statements for the fiscal year ending March 31, 2026, and a final dividend of ₹0.50 per equity share. Mr. Pankaj Sahni was re-elected as a director, and the remuneration for cost auditors for the 2026-27 financial year was also approved. The voting results for these resolutions, conducted via remote e-voting and during the meeting, showed strong approval percentages, with the dividend resolution receiving 99.9997% of valid votes in favour.

- On September 23, 2026, management is scheduled to meet with USS Investment Management Ltd in Gurugram.
- The 22nd Annual General Meeting was held on September 16, 2026.
- Shareholders approved a final dividend of ₹0.50 per equity share for the fiscal year ended March 31, 2026, with 99.9997% of votes in favour.
- Mr. Pankaj Sahni was re-elected as a director with 99.7679% of votes in favour.
- Management participated in investor and analyst forums including Jefferies India Forum 2026 (September 17, 2026) and Kotak Healthcare Forum 2026 (September 18, 2026).

- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Global Health Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 16, 2026 |SUBJECT: Shareholders meeting
- Global Health Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 16, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- GLOBAL HEALTH LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Global Health Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- GLOBAL HEALTH LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Global Health Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Global Health, trading on the NSE, has shown a consistent upward trend in its revenue from operations over the reported periods. Revenue grew from ₹1,121.05 crore in Q3 FY2025-26 to ₹1,304.05 crore in Q1 FY2026-27. This revenue growth has been accompanied by an increase in profit before tax, which rose from ₹119.78 crore in Q3 FY2025-26 to ₹213.26 crore in Q1 FY2026-27. The profit for the period also saw an increase, moving from ₹95.03 crore in Q3 FY2025-26 to ₹157.25 crore in Q1 FY2026-27. The company's expenses have also risen, but at a pace that has allowed for improved profitability. Tax expense has followed a similar upward trajectory as profits. Comprehensive income for the period has also shown growth, from ₹95.65 crore in Q3 FY2025-26 to ₹152.09 crore in Q1 FY2026-27.

- Revenue from operations increased sequentially from ₹1,121.05 crore in Q3 FY2025-26 to ₹1,159.05 crore in Q4 FY2025-26, and further to ₹1,304.05 crore in Q1 FY2026-27.
- Profit Before Tax grew from ₹119.78 crore in Q3 FY2025-26 to ₹187.28 crore in Q4 FY2025-26, and reached ₹213.26 crore in Q1 FY2026-27.
- Profit Loss For Period increased from ₹95.03 crore in Q3 FY2025-26 to ₹141.65 crore in Q4 FY2025-26, and was ₹157.25 crore in Q1 FY2026-27.
- Comprehensive Income For The Period rose from ₹95.65 crore in Q3 FY2025-26 to ₹145.37 crore in Q4 FY2025-26, and stood at ₹152.09 crore in Q1 FY2026-27.

### Bull Case

The company's stock shows several technical indicators suggesting a constructive market setup. On a daily timeframe, the closing price of ₹1499.4 is above both the 20-day Exponential Moving Average (EMA) of ₹1441.47 and the 50-day EMA of ₹1406.22. The Supertrend indicator is also 'bullish' at ₹1370.58, indicating upward momentum. Weekly trends reinforce this, with the closing price exceeding the 20-day EMA (₹1356.44) and 50-day EMA (₹1272.9), and the Supertrend signal being 'bullish' at ₹1215.36. The stock has also demonstrated positive returns across various periods, notably a 44% return over the last six months and a 26% year-to-date return.

- As of 2026-09-18, the daily closing price of ₹1499.4 is above the 20-day EMA (₹1441.47) and 50-day EMA (₹1406.22).
- The daily Supertrend indicator is 'bullish' at ₹1370.58.
- The weekly Supertrend indicator is 'bullish' at ₹1215.36.
- The stock has achieved a 44% return in the last six months and a 26% year-to-date return.

### Bear Case

The company's monthly trend indicators suggest a cautionary outlook, with the Supertrend indicator at ₹1559.82 indicating a bearish signal on a monthly timeframe. While daily and weekly trends show bullish Supertrend signals, the monthly perspective warrants attention. The stock has experienced a maximum drawdown of -33% historically, and its current annualized volatility stands at 32%.

- The monthly Supertrend indicator is bearish at ₹1559.82 as of 2026-09-18.
- The stock has a historical maximum drawdown of -33%.
- Annualized volatility is recorded at 32%.

### FAQs

**What were the key outcomes of Global Health Limited's Annual General Meeting on September 16, 2026?**

During the 22nd Annual General Meeting held on September 16, 2026, shareholders approved the audited financial statements for the fiscal year ended March 31, 2026. A final dividend of ₹0.50 per equity share was declared. Additionally, Mr. Pankaj Sahni was re-elected as a director, and the remuneration for cost auditors M/s Ramanath Iyer & Co. for the 2026-27 financial year was approved. Voting results indicated strong approval for these resolutions, with the dividend resolution receiving 99.9997% of valid votes in favour.

**What is the current technical trend for Global Health Limited as of September 18, 2026?**

As of September 18, 2026, the daily technical trend for Global Health Limited is indicated as 'bullish' by the Supertrend indicator, which is positioned at 1370.58. The closing price was ₹1499.4. Key moving averages show the 20-day Exponential Moving Average (EMA) at 1441.47 and the 50-day EMA at 1406.22, both below the current price. However, the monthly trend is indicated as 'bearish' by the Supertrend, which is at 1559.82.

**What recent investor engagement activities has Global Health Limited participated in?**

Global Health Limited's management has scheduled or participated in several investor engagement events. On September 17, 2026, management met with USS Investment Management Ltd in Gurugram. Prior to that, on September 17 and 18, 2026, management attended the Jefferies India Forum 2026 in Gurugram and the Kotak Healthcare Forum 2026 in Mumbai, respectively. These meetings were conducted in person, with no unpublished price-sensitive information intended for sharing.

**How has Global Health Limited's stock performed over different periods leading up to September 18, 2026?**

As of September 18, 2026, Global Health Limited's stock has shown varied returns across different timeframes. Year-to-date (YTD) return was 0.26. Over the last six months, the stock returned 0.44. Shorter-term returns include 0.19 for three months and 0.04 for one month. Longer-term returns show 0.10 for one year and 0.06 for ten years. The return since the start of trading is 0.36.

- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Global Health Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 16, 2026 |SUBJECT: Shareholders meeting
- Global Health Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 16, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Global Health Limited has informed the Exchange about Schedule of meet. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,422.17
- Risk regime: Price Risk Requires Attention

### Support levels
- 1365.3
- 1153.375
- 1133.45

### Resistance levels
- 1544

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +5.29% |
| return_10 | +5.79% |
| return_1m | +3.93% |
| return_1y | +9.63% |
| return_20 | +6.48% |
| return_3m | +19.17% |
| return_5 | +2.73% |
| return_6m | +43.62% |
| return_since_start | +36.22% |
| return_ytd | +25.80% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -32.66% |
| annualized_volatility | +31.61% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue expansion outpaces cost growth, yet net profit remains steady year on year

Global Health Limited reported results for the quarter ended 30 June 2026, posting its highest quarterly revenue in the available series. Revenue rose 26.5% from a year ago to ₹1,304.05 crore. While profit before tax also reached a new peak, net profit stayed virtually unchanged compared to the same quarter last year, as higher operating costs, increased finance charges, and a higher tax rate offset the top-line gains.

## Revenue and Expense Trends

Revenue from operations has climbed over the past five quarters, with the June 2026 quarter showing a notably larger sequential jump. Revenue rose ₹145.00 crore quarter-on-quarter to ₹1,304.05 crore, an increase of 12.5%. This follows an average sequential rise of roughly ₹43 crore in the preceding three quarters. Year on year, revenue grew by ₹273.21 crore, or 26.5%.

Total expenses rose to ₹1,112.95 crore, up 10.4% sequentially and 29% year on year. Over the trailing twelve months, expense growth exceeded revenue growth by 2.5 percentage points. Sequentially, however, expense growth of 10.4% lagged behind revenue growth of 12.5%, contributing to the quarter-on-quarter rise in profit before tax.

## Profitability and Margins

Profit before tax increased 13.9% sequentially to ₹213.26 crore, the highest level in the series. Year on year, profit before tax rose 2.5% to ₹213.26 crore from ₹208.14 crore.

Despite the absolute growth in profit before tax, margins compressed. The profit before tax margin fell from 20.2% in the year-ago quarter to 16.4% in the current quarter. The net profit margin declined from 15.4% to 12.1%. The gap between revenue growth and profit growth reflects the combined effect of higher operating expenses, increased finance costs, and a higher effective tax rate.

## Cost Structure

Employee benefit expense was the largest single cost at ₹319.27 crore, representing 24.5% of revenue. Cost of materials consumed (₹257.19 crore) and purchases of stock-in-trade (₹40.73 crore) together accounted for 22.8% of revenue. Depreciation and amortisation of ₹68.98 crore made up 5.3% of revenue. The sequential expense increase of ₹104.44 crore was driven by these operating costs, though a detailed breakdown for prior quarters is not available for direct comparison.

## Finance Costs and Tax

Finance costs have risen over the past year, from ₹13.79 crore in Q1 FY2026 to ₹26.68 crore in the current quarter, a 93.5% increase. Sequentially, finance costs were essentially flat, decreasing by ₹0.03 crore from the previous quarter.

Tax expense rose to ₹56.01 crore, up 22.8% sequentially and 13.9% year on year. The effective tax rate increased to 26.3% from 23.6% a year ago, which reduced net profit growth.

## Earnings and Comprehensive Income

Basic earnings per share were ₹5.91, nearly identical to ₹5.92 a year ago. Diluted earnings per share were ₹5.90. The stability in earnings per share despite higher revenue underscores the margin compression.

Comprehensive income for the period was ₹152.09 crore, down 4.5% year on year. This decline occurred as an other comprehensive loss of ₹5.16 crore (net of tax) reduced the net profit figure of ₹157.25 crore.

## Management Commentary

Global Health Limited reported consolidated revenue of Rs. 13,040.51 million for the quarter ended June 30, 2026, reflecting growth from Rs. 10,308.44 million in the prior year period. Profit after tax was recorded at Rs. 1,572.52 million, with earnings per share at Rs. 5.91. The company also declared a final dividend of Rs. 0.50 per equity share for FY2025-26, subject to shareholder approval at the upcoming AGM.

Strategic expansion continues with the approval of a revised construction plan for the upcoming Guwahati hospital, increasing bed capacity from 400 to 650 beds. This Rs. 970 crore project, funded through internal accruals and debt, targets a 50 million population base in the North East over the next 3-4 years. Additionally, the company appointed a Chief Digital Officer to enhance technology leadership and digital transformation initiatives.

## Key Takeaway

Global Health delivered rapid revenue expansion during the June 2026 quarter, reaching a new high. However, the benefit of that growth was offset by rising expenses, higher finance costs, and a higher tax rate, leaving net profit essentially flat compared with a year ago. Profit before tax did reach a new record, but margins narrowed. The quarter shows that while the top line is growing rapidly, translating that growth into proportional profit improvement remains a challenge in the current cost environment.

### Ratios

## Official filings

- 2026-09-17 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_17092026131726_GHLANALYSTSMEETSEPTEMBER172026Signed.pdf)
- 2026-09-16 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_16092026161008_GHLAGMPROCEEDINGS16SEP2026Signed.pdf)
- 2026-09-16 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_16092026182437_GHLAGMVOTINGRESANDSCRREPORT16SEP2026FINAL.pdf)
- 2026-09-11 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_11092026160351_GHLANALYSTSMEETSEPTEMBER112026Signed.pdf)
- 2026-09-11 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_11092026160414_GHLANALYSTSMEETSEPTEMBER112026Signed.pdf)
- 2026-09-11 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260911_162246560.xml)
- 2026-09-09 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_09092026192710_GHLANALYSTSMEETSEPTEMBER092026signed.pdf)
- 2026-09-06 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260906_120528193.xml)
- 2026-09-03 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03092026164810_GHLANALYSTSMEETSEPTEMBER32026Signed.pdf)
- 2026-09-03 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03092026164756_GHLANALYSTSMEETSEPTEMBER32026Signed.pdf)
- 2026-08-31 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_31082026161643_GHLANALYSTSMEETAUG312026Signed.pdf)
- 2026-08-31 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260831_163445028.xml)
- 2026-08-25 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_25082026144428_GHLANALYSTSMEETAUGUST252026Signed.pdf)
- 2026-08-25 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260825_144939839.xml)
- 2026-08-22 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_22082026124909_GHLPOSTDISPATCHADV22AUG2026FINALSIGNED.pdf)
- 2026-08-22 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_22082026162515_GHLANALYSTSMEETAUGUST222026Sign.pdf)
- 2026-08-22 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260822_163834519.xml)
- 2026-08-22 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_22082026162701_GHLANALYSTSMEETAUGUST222026Sign.pdf)
- 2026-08-21 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_21082026173343_GHLAGMNOTICE21AUG2026Signed.pdf)
- 2026-08-21 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_20051_WebXMLFile_20260821_180410777.xml)
- 2026-08-21 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_21082026181913_GHLBRSRINTIMATION21AUG2026Signed.pdf)
- 2026-08-21 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_21082026185510_GHLLETTERTOSHAREHOLDERS21AUG2026Signed.pdf)
- 2026-08-20 — Annual Report: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_30497_MEDANTA_2025_2026_A_17778854_21082026174714.pdf)
- 2026-08-18 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20260818_181911124.xml)
- 2026-08-18 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_18082026181007_GHLANALYSTSMEETAUGUST182026Signed.pdf)

## News and market events

- 2026-09-10 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —10 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — One 97 Communications, Global Health, Adani Power, JSW Infrastructure, and Aditya Birla Sun Life Amc. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-10-september-2026-11789001772273.html)
- 2026-09-07 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —7 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — TCPL Packaging, Innova Captab, Greenply Industries, Global Health, and Apl Apollo Tubes. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-7-september-2026-11788742187187.html)
- 2026-09-01 — Mint: **Stocks to buy for short term: Sagility, Polycab India among 6 stocks experts recommend buying today; do you own any?** — Stocks to buy for the short term: Experts highlight six stocks to buy for short-term gains, backed by robust technical indicators and market momentum. Dive into the analysis to learn more. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-buy-for-short-term-sagility-polycab-india-among-6-stocks-experts-recommend-buying-today-do-you-own-any-11788234015790.html)
- 2026-08-28 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —28 August 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —Wonderla Holidays, Orkla India, Bharat Heavy Electricals, Adani Power, and Global Health. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-28-august-2026-11787878851830.html)
- 2026-08-26 — MONEYCONTROL: **Buy Global Health; target of Rs 1750: Prabhudas Lilladher** — Prabhudas Lilladher, Global Health, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-global-health-target-of-rs-1750-prabhudas-lilladher-14015922.html)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty may open above 24,500; Auto stocks in focus** — Sensex Today | Stock Market Live Updates: The bulls, having ended the week with gains will now be eyeing two levels on the upside, 24,467, which is the recent swing high, and 24,500, which has been a psychological barrier, before the positional swing high of 24,601 could be retested. The Nifty Bank though, continues to struggle with 57,500 continuing to act as a hurdle. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-07-31 — CNBC-TV18: **Q1 Results LIVE Updates: Hyundai Motor India shares rise over up 9%; ITC, Maruti report today** — Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sun-pharma-itc-maruti-suzuki-bajaj-finserv-tata-steel-swiggy-share-price-liveblog-19958383.htm)
- 2026-07-24 — Mint: **Raja Venkatraman recommends three stocks for 24 July** — Market expert Raja Venkatraman shares his top stock picks for 24 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-24-july-sensex-nifty-11784818333324.html)
- 2026-07-23 — Economic Times: **India has undertaken transformative reforms to strengthen its healthcare system: J P Nadda** — India hosted the 16th BRICS Health Ministers' Meeting in Chandigarh. The meeting established a network for mental wellness research and collaboration. BRICS nations adopted a declaration to deepen health cooperation and strengthen systems. Initiatives were launched to combat diseases driven by social determinants. Digital health and healthy lifestyle promotion were also key discussion points. — [Source](https://economictimes.indiatimes.com/news/india/india-has-undertaken-transformative-reforms-to-strengthen-its-healthcare-system-j-p-nadda/articleshow/132582549.cms)
- 2026-07-15 — Times of India: **Over 700 dead in Ebola outbreak in DR Congo: First-ever human trial of Bundibugyo Ebola vaccine — when will it be ready?** — Wellness News: More than 700 people have died in the latest Ebola outbreak tearing through the Democratic Republic of the Congo — the worst the country has ever seen. — [Source](https://timesofindia.indiatimes.com/etimes/wellness/over-700-dead-in-ebola-outbreak-in-dr-congo-first-ever-human-trial-of-bundibugyo-ebola-vaccine-when-will-it-be-ready/articleshow/132403515.cms)

## Business profile

**Strategic vision:** Multi-specialty tertiary care provider delivering advanced healthcare services.

### Business segments
- **Hospital Operations:** Medanta operates hospitals providing advanced medical treatments across a broad range of specialties. They focus on integrated, multispecialty care delivered by experienced superspecialist doctors.
- **Ancillary Healthcare Services:** The company offers complementary services including medicine delivery, lab tests, diagnostics, homecare, virtual consultations, and air ambulance services to provide comprehensive patient care.

### Competitive strengths
- Integrated multispecialty care delivery model
- Network of advanced tertiary care hospitals
- Team of experienced superspecialist doctors
- Comprehensive suite of medical and ancillary services

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/medanta
Markdown representation: https://faxioms.com/stocks/medanta?render=md